Kynam Capital Management
Latest statistics and disclosures from Kynam Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NTRA, SNDX, CLDX, PCVX, VERA, and represent 56.61% of Kynam Capital Management's stock portfolio.
- Added to shares of these 10 stocks: ImmunoGen (+$42M), MOR (+$42M), SNDX (+$36M), COGT (+$21M), CORT (+$19M), DVAX (+$14M), VERA (+$11M), TVTX (+$9.2M), BCRX (+$8.8M), LQDA (+$8.4M).
- Started 4 new stock positions in MOR, CORT, ImmunoGen, TYRA.
- Reduced shares in these 10 stocks: NTRA (-$38M), PCVX (-$19M), TSHA (-$10M), CLDX (-$7.7M), IMVT, OLMA, CNTA, VRDN, , CNTB.
- Sold out of its positions in Catalyst Biosciences, CNTB, GOSS, IMVT, Neoleukin Therapeutics, OLMA, PBYI, TSHA.
- Kynam Capital Management was a net buyer of stock by $135M.
- Kynam Capital Management has $903M in assets under management (AUM), dropping by 47.64%.
- Central Index Key (CIK): 0001907884
Tip: Access up to 7 years of quarterly data
Positions held by Kynam Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Kynam Capital Management
Kynam Capital Management holds 24 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Natera (NTRA) | 16.7 | $150M | -20% | 2.4M | 62.64 |
|
| Syndax Pharmaceuticals (SNDX) | 13.6 | $122M | +41% | 5.7M | 21.61 |
|
| Celldex Therapeutics Com New (CLDX) | 13.2 | $119M | -6% | 3.0M | 39.66 |
|
| Vaxcyte (PCVX) | 7.0 | $63M | -23% | 1.0M | 62.80 |
|
| Vera Therapeutics Cl A (VERA) | 6.2 | $56M | +23% | 3.7M | 15.38 |
|
| Protagonist Therapeutics (PTGX) | 5.1 | $46M | +10% | 2.0M | 22.93 |
|
| ImmunoGen | 4.7 | $42M | NEW | 1.4M | 29.65 |
|
| Morphosys Sponsored Ads (MOR) | 4.6 | $42M | NEW | 4.2M | 9.90 |
|
| Cogent Biosciences (COGT) | 3.8 | $34M | +164% | 5.9M | 5.88 |
|
| Liquidia Corporation Com New (LQDA) | 3.6 | $33M | +34% | 2.7M | 12.03 |
|
| BioCryst Pharmaceuticals (BCRX) | 3.1 | $28M | +46% | 4.6M | 5.99 |
|
| 2seventy Bio Common Stock (TSVT) | 2.8 | $25M | 6.0M | 4.27 |
|
|
| Dynavax Technologies Corp Com New (DVAX) | 2.3 | $21M | +202% | 1.5M | 13.98 |
|
| Wave Life Sciences SHS (WVE) | 2.2 | $20M | 3.9M | 5.05 |
|
|
| Corcept Therapeutics Incorporated Put Option (CORT) | 2.1 | $19M | NEW | 586k | 32.48 |
|
| Travere Therapeutics (TVTX) | 2.0 | $18M | +105% | 2.0M | 8.99 |
|
| Miragen Therapeutics (VRDN) | 1.5 | $13M | -13% | 608k | 21.78 |
|
| Amarin Corp Spons Adr New (AMRN) | 1.2 | $11M | 12M | 0.87 |
|
|
| Acelyrin (SLRN) | 1.0 | $9.0M | 1.2M | 7.46 |
|
|
| Sutro Biopharma (STRO) | 1.0 | $8.6M | +28% | 2.0M | 4.29 |
|
| Burning Rock Biotech Sponsored Ads (BNR) | 0.9 | $8.1M | +2% | 8.7M | 0.93 |
|
| Caribou Biosciences (CRBU) | 0.7 | $6.1M | 1.1M | 5.73 |
|
|
| Tyra Biosciences (TYRA) | 0.5 | $4.7M | NEW | 340k | 13.85 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.4 | $3.5M | -39% | 443k | 7.96 |
|
Past Filings by Kynam Capital Management
SEC 13F filings are viewable for Kynam Capital Management going back to 2021
- Kynam Capital Management 2023 Q4 filed Feb. 14, 2024
- Kynam Capital Management 2023 Q3 filed Nov. 14, 2023
- Kynam Capital Management 2023 Q2 filed Aug. 14, 2023
- Kynam Capital Management 2023 Q1 filed May 15, 2023
- Kynam Capital Management 2022 Q4 filed Feb. 14, 2023
- Kynam Capital Management 2022 Q3 filed Nov. 14, 2022
- Kynam Capital Management 2022 Q2 filed Aug. 15, 2022
- Kynam Capital Management 2022 Q1 filed May 13, 2022
- Kynam Capital Management 2021 Q4 filed Feb. 14, 2022